Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis.

Gonzalez-Gay MA, Garcia-Unzueta MT, Berja A, Gonzalez-Juanatey C, Miranda-Filloy JA, Vazquez-Rodriguez TR, de Matias JM, Martin J, Dessein PH, Llorca J.

Clin Exp Rheumatol. 2009 Mar-Apr;27(2):222-8.

PMID:
19473561
2.

Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy.

Gonzalez-Gay MA, Vazquez-Rodriguez TR, Garcia-Unzueta MT, Berja A, Miranda-Filloy JA, de Matias JM, Gonzalez-Juanatey C, Llorca J.

Clin Exp Rheumatol. 2010 Jan-Feb;28(1):56-62.

PMID:
20346239
3.

Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis.

Gonzalez-Gay MA, Garcia-Unzueta MT, Gonzalez-Juanatey C, Miranda-Filloy JA, Vazquez-Rodriguez TR, De Matias JM, Martin J, Dessein PH, Llorca J.

Clin Exp Rheumatol. 2008 Mar-Apr;26(2):311-6.

PMID:
18565254
4.

Short-term effect of anti-TNF-alpha therapy on nitric oxide production in patients with severe rheumatoid arthritis.

Gonzalez-Gay MA, Garcia-Unzueta MT, Berja A, Vazquez-Rodriguez TR, Miranda-Filloy JA, Gonzalez-Juanatey C, de Matias JM, Martin J, Dessein PH, Llorca J.

Clin Exp Rheumatol. 2009 May-Jun;27(3):452-8.

PMID:
19604438
5.

High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis.

Gonzalez-Gay MA, Llorca J, Garcia-Unzueta MT, Gonzalez-Juanatey C, De Matias JM, Martin J, Redelinghuys M, Woodiwiss AJ, Norton GR, Dessein PH.

Clin Exp Rheumatol. 2008 Jul-Aug;26(4):596-603.

PMID:
18799090
6.

Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis.

Gonzalez-Gay MA, Garcia-Unzueta MT, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J, Llorca J.

Clin Exp Rheumatol. 2006 Jul-Aug;24(4):373-9.

PMID:
16956426
7.

Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis.

Popa C, Netea MG, de Graaf J, van den Hoogen FH, Radstake TR, Toenhake-Dijkstra H, van Riel PL, van der Meer JW, Stalenhoef AF, Barrera P.

J Rheumatol. 2009 Apr;36(4):724-30. doi: 10.3899/jrheum.080626. Epub 2009 Feb 27.

PMID:
19273452
8.

Effects of a 6-month infliximab treatment on plasma levels of leptin and adiponectin in patients with rheumatoid arthritis.

Derdemezis CS, Filippatos TD, Voulgari PV, Tselepis AD, Drosos AA, Kiortsis DN.

Fundam Clin Pharmacol. 2009 Oct;23(5):595-600. doi: 10.1111/j.1472-8206.2009.00717.x. Epub 2009 Jun 25.

PMID:
19563510
9.

Correlation between insulin resistance and serum ghrelin in non-diabetic ankylosing spondylitis patients undergoing anti-TNF-α therapy.

Genre F, López-Mejías R, Miranda-Filloy JA, Carnero-López B, Gómez-Acebo I, Blanco R, Ochoa R, Rueda J, González-Juanatey C, Llorca J, González-Gay MÁ.

Clin Exp Rheumatol. 2013 Nov-Dec;31(6):913-8. Epub 2013 Aug 26.

PMID:
23981480
10.

Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.

Miranda-Filloy JA, López-Mejias R, Genre F, Carnero-López B, Ochoa R, Diaz de Terán T, González-Juanatey C, Blanco R, Llorca J, González-Gay MA.

Clin Exp Rheumatol. 2013 Jul-Aug;31(4):538-45. Epub 2013 May 27.

PMID:
23711190
11.

Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis.

Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J, Llorca J.

Clin Exp Rheumatol. 2006 Jan-Feb;24(1):83-6.

PMID:
16539824
12.

Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade.

Ingegnoli F, Fantini F, Favalli EG, Soldi A, Griffini S, Galbiati V, Meroni PL, Cugno M.

J Autoimmun. 2008 Sep;31(2):175-9. doi: 10.1016/j.jaut.2008.07.002. Epub 2008 Aug 15.

PMID:
18707846
13.

Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.

Miranda-Filloy JA, López-Mejias R, Genre F, Carnero-López B, Ochoa R, Diaz de Terán T, González-Juanatey C, Blanco R, Llorca J, González-Gay MA.

Clin Exp Rheumatol. 2013 May-Jun;31(3):365-71. Epub 2013 Jan 23.

PMID:
23294554
14.

Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis.

Macías I, García-Pérez S, Ruiz-Tudela M, Medina F, Chozas N, Girón-González JA.

J Rheumatol. 2005 Nov;32(11):2102-8.

PMID:
16265686
15.

Plasma leptin and neuropeptide Y concentrations in patients with rheumatoid arthritis treated with infliximab, a TNF-α antagonist.

Kopec-Medrek M, Kotulska A, Widuchowska M, Adamczak M, Więcek A, Kucharz EJ.

Rheumatol Int. 2012 Nov;32(11):3383-9. doi: 10.1007/s00296-011-2182-6. Epub 2011 Nov 3.

16.

Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis.

Popa C, Netea MG, Radstake TR, van Riel PL, Barrera P, van der Meer JW.

Ann Rheum Dis. 2005 Aug;64(8):1195-8. Epub 2005 Feb 24.

17.

Disease activity improvement in rheumatoid arthritis treated with tumor necrosis factor-α inhibitors correlates with increased soluble Fas levels.

Romano E, Terenzi R, Manetti M, Peruzzi F, Fiori G, Nacci F, Bellando-Randone S, Matucci-Cerinic M, Guiducci S.

J Rheumatol. 2014 Oct;41(10):1961-5. doi: 10.3899/jrheum.131544. Epub 2014 Sep 1.

PMID:
25179850
19.

Regulation of serum chemokines following infliximab therapy in patients with rheumatoid arthritis.

Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J.

Clin Exp Rheumatol. 2006 Sep-Oct;24(5):529-33.

PMID:
17181921
20.

Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients.

Song SN, Iwahashi M, Tomosugi N, Uno K, Yamana J, Yamana S, Isobe T, Ito H, Kawabata H, Yoshizaki K.

Arthritis Res Ther. 2013 Oct 2;15(5):R141. doi: 10.1186/ar4323.

Supplemental Content

Support Center